3034 results for "Psilocybin"
Psilocybin-Assisted Group Therapy and Attachment: Observed Reduction in Attachment Anxiety and Influences of Attachment Insecurity on the Psilocybin Experience
ACS Pharmacology & Translational Science – December 09, 2020
Summary
Psilocybin, a potent hallucinogen, can significantly reduce attachment anxiety, a known psychopathology risk factor. In Clinical psychology, a study with 18 long-term AIDS survivors found a single psilocybin session decreased self-reported attachment anxiety over three months (effect size d=0.45). This work, relevant to Psychiatry and Psychedelics and Drug Studies, reveals baseline attachment anxiety (r=0.53) and avoidance (r=0.62) influence session experiences. Psychotherapists can leverage these insights from Psychology and Attachment theory to optimize psychopathology treatments.
Abstract
Attachment insecurity is determined early in life, is a risk factor for psychopathology, and can be measured on two separate continuous dimensions:...
Psilocybin-gestützte Therapie von Depression, Angst und Suchtstörungen: Neurobiologische Grundlagen und klinische Anwendung
Fortschritte der Neurologie · Psychiatrie – May 19, 2023
Summary
Psilocybin-assisted psychotherapy offers profound hope for mental health, especially when conventional medicine fails. This unique approach, involving a psychotherapist and controlled doses of the hallucinogen Psilocybin, has shown long-term positive effects after just one to a few sessions in initial Psychology and Psychiatry investigations. Its therapeutic mechanisms involve neurotransmitter receptor influence. Growing interest in Psychedelics and Drug Studies and Complementary and Alternative Medicine Studies has led to approval for larger clinical trials, signaling a potential paradigm shift in mental healthcare.
Abstract
Zusammenfassung Eine erfolgreiche Therapie psychischer Störungen ist angesichts des häufig vorhandenen Leidensdrucks der Betroffenen sehr wichtig. ...
"I've learned that I'm open-minded to this possibility": A qualitative study to evaluate the acceptability of a psilocybin-aided smoking cessation treatment for people with HIV who smoke.
Addiction science & clinical practice – July 21, 2025
Summary
A notable finding: People with HIV, who often face unique challenges quitting tobacco, show significant openness to a novel psilocybin-assisted tobacco treatment. This qualitative study explored perceptions of using psilocybin for smoking cessation among this group. Interviews revealed that despite some initial uncertainties, participants were ultimately willing to try this unique tobacco treatment. The findings suggest psilocybin-aided therapy is acceptable for those with HIV seeking to quit tobacco.
Abstract
People with HIV (PWH) are disproportionately affected by cigarette use, with a 40 - 70% prevalence rate. Although many express a strong interest in...
Psilocybin-assistierte Gruppenpsychotherapie bei Abhängigkeitserkrankungen
SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice – December 01, 2025
Summary
A pioneering Swiss program has safely delivered 89 psilocybin-assisted group therapy treatments to 36 patients with addiction, reporting no severe complications. This structured approach, implemented over 12 cycles, integrates extensive preparation and follow-up within a supportive group setting. It fosters belonging and compassion, demonstrating potential for individuals struggling with treatment-resistant addiction, though requiring significant expertise and resources to implement effectively.
Abstract
Zusammenfassung: Hintergrund: In der Schweiz kann Psilocybin im Rahmen von Ausnahmebewilligungen therapeutisch genutzt werden. Programm: Die Klinik...
Psilocybin-Assisted Compassion Focused Therapy for Depression
Frontiers in Psychology – March 25, 2022
Summary
Psilocybin, a potent hallucinogen, demonstrates significant efficacy, with studies showing it reduces depressive symptoms by over 50% for many patients. To enhance these benefits, a new clinical psychology protocol integrates Compassion Focused Therapy (CFT) into psilocybin-assisted psychotherapy. This framework provides psychotherapists with specific guidance, emphasizing compassion practices and mindfulness throughout the typical three-phase treatment. The aim is to deepen psychological insights during therapy sessions, potentially improving outcomes in psychiatry and advancing psychotherapy techniques within psychedelics and drug studies, and complementary medicine applications.
Abstract
Psilocybin-assisted psychotherapy, i.e., psilocybin treatment with psychological support, has demonstrated the efficacy of psilocybin to reduce dep...
Effects of psilocybin-assisted therapy on treatment-resistant depression
European Psychiatry – April 01, 2021
Summary
A compelling finding in mental health research shows that psilocybin, a classic hallucinogen, offers significant hope for treatment-resistant depression (TRD). In studies involving 32 patients with major depressive disorder, two doses of psilocybin alongside psychological support dramatically improved mood. All participants experienced symptom reduction, with substantial antidepressant effects sustained for up to six months. This serotonergic compound represents a promising new medicine for psychiatry, potentially transforming clinical psychology approaches to severe depression.
Abstract
Introduction Major depressive disorder is a highly prevalent clinical condition, affecting more than 300 million individuals worldwide. About 1/3 o...
Transient Elevation of Plasma Glucocorticoids Supports Psilocybin-Induced Anxiolysis in Mice
ACS Pharmacology & Translational Science – August 02, 2023
Summary
Psilocybin's long-term anxiolytic effects stem from a temporary stress hormone surge, not its hallucinogenic properties. In C57BL/6 male mice, 3 mg/kg psilocybin produced anxiolytic effects lasting 7 days. This pharmacology was blocked by a glucocorticoid receptor antagonist, an antiglucocorticoid, or suppressing corticosterone. A non-hallucinogen 5-HT2A agonist also showed anxiolytic effects via similar glucocorticoid release. This endocrinology, relevant to internal medicine and drug studies, suggests acute psilocybin-induced glucocorticoid release drives the post-acute anxiolytic action, but chronic corticosterone elevation negates it.
Abstract
While correlations between drug-induced cortisol elevation, self-reported anxiety, and treatment outcomes have been reported for human studies duri...
Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer
Journal of Psychopharmacology – January 09, 2020
Summary
Psilocybin, a psychedelic hallucinogen, alongside a psychotherapist, offered profound, long-term relief from cancer-related psychiatric and existential distress. A 4.5-year follow-up of 15 participants showed 60–80% maintained clinically significant improvements in anxiety and depression, with large effect sizes. This medicine enhances quality of life for clinical psychology and psychiatry. Participants (71–100%) attributed positive life changes to the experience, rating it among their most meaningful spiritual or even paranormal experiences, highlighting its complementary medicine potential.
Abstract
Background: A recently published randomized controlled trial compared single-dose psilocybin with single-dose niacin in conjunction with psychother...
Psilocybin-Induced Neuroplasticity and Sustained Antidepressant Effects
Quality in Sport – January 31, 2026
Summary
Psilocybin-assisted psychological intervention rapidly reduces depressive symptoms, with effects lasting six months in some treatment-resistant depression protocols. This compelling finding in clinical psychology highlights a key neuroscience mechanism: neuroplasticity. Serotonergic activation leads to structural synaptic remodeling, observed in preclinical work and human functional neuroimaging. This biological mechanism, supported by studies on extinction learning relevant to exposure therapy, suggests how psychedelics exert their antidepressant effects. The medicine offers a promising avenue for sustained improvement, linking transient drug effects to enduring psychological change.
Abstract
Psilocybin-assisted interventions have shown rapid reductions in depressive symptoms in controlled clinical settings, raising questions about biolo...
Psilocybin-assisted massed cognitive processing therapy for chronic posttraumatic stress disorder: Protocol for an open-label pilot feasibility trial
PLoS ONE – January 17, 2025
Summary
Posttraumatic stress affects 3.9% of the population, often resisting standard cognitive behavioral therapies like cognitive processing therapy. A pilot in psychiatry is exploring if a single 25 mg dose of psilocybin, a potent hallucinogen from chemical synthesis and alkaloids studies, can enhance outcomes. Fifteen participants with chronic Posttraumatic stress will combine this psychedelic medicine with a week of intensive cognitive processing. This psychology-informed approach aims to improve cognition and offer a vital alternative. Digital mental health interventions will monitor progress.
Abstract
Background Posttraumatic stress disorder (PTSD) affects 3.9% of the general population. While massed cognitive processing therapy (CPT) has demonst...
Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction
Current Drug Abuse Reviews – January 09, 2015
Summary
A compelling 80% of 15 participants achieved verified smoking abstinence at six months in a pilot study exploring psilocybin, an alkaloid, for addiction treatment. This clinical psychology research, part of broader psychedelics and drug studies, suggests the hallucinogen's therapeutic potential. Successful smoking cessation was strongly linked to profound mystical experiences, reported by 60% of participants, rather than general drug intensity. This highlights how the unique psychological context of these experiences, fostering openness to experience and reducing craving, can be a powerful medicine in psychiatry, guiding individuals towards lasting abstinence.
Abstract
Psilocybin-occasioned mystical experiences have been linked to persisting effects in healthy volunteers including positive changes in behavior, att...
Psilocybin-assisted psychotherapy for cancer patients
International Journal of Whole Person Care – January 29, 2024
Summary
Compelling evidence indicates Psilocybin-assisted psychotherapy, guided by a psychotherapist, offers a safe and effective treatment for profound demoralization and death anxiety in patients with advanced cancer. This medicine, rooted in psychology and indigenous traditions, uses either natural or synthetic psilocybin. A pioneering case series in Quebec's public healthcare system successfully integrated these psychedelics, demonstrating their potential. This advancement in drug studies, involving chemical synthesis and alkaloids, provides hope, despite persistent societal stigma.
Abstract
Despite significant advances in symptom management for patients affected by serious illness, physicians lack effective legal treatments for individ...
Psilocybin-assisted therapy and depression - a systematic review
Open Repository of the University of Porto (University of Porto) – June 05, 2020
Summary
Psilocybin-assisted therapy offers immediate, substantial improvements for depression, lasting up to six months. A review of four clinical trials, involving 32 patients with treatment-resistant depression and 80 patients with cancer-related anxiety and depression, highlights its potential in Psychology and Mental Health. This promising approach, rooted in the history of Psychedelics and Drug Studies, suggests a new avenue in Medicine for psychotherapists. While the Humanities have long explored altered states, these findings underscore psilocybin's therapeutic promise, inviting further philosophical and psychological inquiry.
Abstract
Background: Psilocybin is a naturally occurring serotonin receptor agonist that can be, more commonly, found in the Psilocybe mushrooms. Consumed b...
Synergistic Behavioral and Neuroplastic Effects of Psilocybin-NMDAR Modulator Administration
OpenAlex – November 28, 2024
Summary
Combining psilocybin, a potent alkaloid, with NMDA receptor modulators can enhance its therapeutic potential and mitigate adverse effects. In ICR male mice, psilocybin-induced head twitches were dose-dependently reduced. Neuroscience in Psychedelics and Drug Studies also revealed increased neuroplasticity: psilocybin-D-serine boosted GAP43 across all 4 brain regions; psilocybin-D-cycloserine elevated PSD95 across all 4. This strategy, influencing neurotransmitter receptors, offers a safer path for psychology, optimizing treatment.
Abstract
Abstract The full therapeutic potential of serotonergic psychedelics (SP) in treating neuropsychiatric disorders, such as depression and schizophre...
Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomized semi-naturalistic-lab feasibility study
Philosophical Transactions of the Royal Society B Biological Sciences – October 21, 2024
Summary
Individuals receiving psilocybin-assisted neurofeedback reported significant self-reported improvements in daily executive functions, crucial for mental health and physical medicine and rehabilitation. This novel treatment, leveraging neuroplasticity and neurotransmitter receptor influence on behavior, involved 37 participants. The 18 individuals in the experimental group experienced substantial gains in working memory and inhibition (medium to high effect sizes). This development in Psychology and Psychedelics and Drug Studies offers a new avenue for addressing anxiety and depression by enhancing neurocognitive processes, validated through psychometrics.
Abstract
Executive function deficits, common in psychiatric disorders, hinder daily activities and may be linked to diminished neural plasticity, affecting ...
Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomised semi-naturalistic-lab feasibility study
OpenAlex – October 11, 2023
Summary
Daily executive functions significantly improved for individuals undergoing psilocybin-assisted neurofeedback. This approach, combining a potent psychedelic from chemical synthesis with targeted brain training, leverages neuroplasticity to enhance mental flexibility. In a group of 18 participants, self-reported gains in working memory and inhibition showed medium to high effect sizes. While 19 controls also reported some benefits, the experimental group achieved their key training goals. This suggests a promising avenue in Psychology and Physical medicine and rehabilitation, exploring neurotransmitter receptor influence on behavior through novel Psychedelics and Drug Studies.
Abstract
Executive function deficits, common in psychiatric disorders, hinder daily activities and may be linked to diminished neural plasticity, affecting ...
Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development.
Fungal biology – April 01, 2022
Summary
No Summary
Abstract
Therapeutic use of psilocybin has become a focus of recent international research, with preliminary data showing promise to address a range of trea...
Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: an fMRI pilot study
Scientific Reports – February 07, 2024
Summary
A single 25 mg dose of the hallucinogen psilocybin significantly diminishes alcohol craving. In 11 patients with alcohol use disorder (5 receiving psilocybin, 6 a placebo), functional magnetic resonance imaging (fMRI) revealed profound changes. Psilocybin, an alkaloid often from chemical synthesis, increased prefrontal cortex activity while decreasing insular cortex engagement, impacting cue reactivity. This neuroscience and psychology finding suggests improved emotional regulation. The supramarginal gyrus also showed unique changes. Such insights into neurotransmitter receptor influence on behavior are vital for medicine, drug studies, and even audiology.
Abstract
Abstract This pilot study investigated psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use d...
300 Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: An fMRI pilot study
Journal of Clinical and Translational Science – April 01, 2024
Summary
Psilocybin profoundly rewired brain responses to alcohol and emotional cues in patients with Alcohol Use Disorder. A pilot neuroscience study of 11 adults revealed that a single 25mg dose of this hallucinogen increased activity in brain regions associated with goal-directed action and emotional regulation, such as the prefrontal cortex. Simultaneously, functional connectivity analysis showed decreased activity in areas linked to craving. This psychological shift, observed in 5 psilocybin recipients versus 6 placebo patients, suggests psilocybin could diminish cue reactivity, offering a promising avenue for psychiatry and clinical psychology in treating alcohol addiction.
Abstract
OBJECTIVES/GOALS: This pilot study investigated psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alco...
Psilocybin-occasioned Mystical-Type Experiences and Mental Wellness
OpenAlex – August 29, 2025
Summary
A single dose of the hallucinogen Psilocybin can profoundly transform lives, leading to significant positive behavioral changes, like ceasing alcohol and nicotine use. Eight individuals in New Zealand, exploring mental wellness, reported mystical experiences characterized by oneness and higher reality. These Psychedelics and Drug Studies suggest that such experiences, rooted in Psychology, foster personal growth and spiritual well-being. The profound impact highlights Psilocybin's potential, even without a Psychotherapist, for deep personal change and mental wellness.
Abstract
<p><strong>Psilocybin, the psychoactive compound found in certain mushrooms, has gained increasing attention for its potential therapeu...
Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects.
NeuroImage – August 01, 2019
Summary
No Summary
Abstract
Both psychedelics and meditation exert profound modulatory effects on consciousness, perception and cognition, but their combined, possibly synergi...
Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review
Cureus – February 05, 2022
Summary
Psilocybin, a classic hallucinogen, is emerging as a powerful medicine in psychiatry. Clinical trials reveal significant reductions in anxiety and mood disorders compared to placebo, and comparable efficacy to SSRIs in one study. This pharmacology, rooted in the unique Neurotransmitter Receptor Influence on Behavior of this chemical (an alkaloid), is revolutionizing addiction treatment. Small open-label Psychedelics and Drug Studies show psilocybin's superiority over traditional therapies for alcohol addiction, offering new hope for complex conditions.
Abstract
Psilocybin-containing mushrooms have been consumed by various cultures in many different parts of the world for thousands of years. Psilocybin, a c...
Attitudes Towards Psilocybin: A General Population’s Opinions on Psilocybin and Psilocybin-Assisted Therapies
Psi Chi Journal of Psychological Research – January 01, 2025
Summary
Overall attitudes towards psilocybin-assisted therapies are positive, suggesting a growing receptiveness to these innovative treatments. A survey of 235 individuals revealed that prior knowledge of psilocybin and experience with psychedelics correlated with more favorable views. This insight, crucial for Psychedelics and Drug Studies, indicates that as the therapeutic potential of compounds derived through chemical synthesis and alkaloids is further explored, public acceptance may expand. Men, Democrats, and atheists also reported more positive attitudes.
Abstract
Psilocybin-assisted therapies (PAT) have been used to treat several issues including obsessive-compulsive disorder (OCD), major depressive disorder...
Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients.
Journal of affective disorders – February 15, 2023
Summary
Cancer patients experiencing depression found remarkable healing through psilocybin therapy, with improvements in their psycho-spiritual well-being lasting at least 8 weeks. The treatment combined group sessions with a single 25mg dose, showing significant positive changes in connection, trust, and self-reflection. NIH-HEALS scores revealed up to 22% improvement in key measures of emotional and spiritual wellness.
Abstract
While psychedelics have been shown to improve psycho-spiritual well-being, the underlying elements of this change are not well-characterized. The N...
Neural correlates of the personality factor openness before and after psilocybin-therapy to depressed patients
Zenodo (CERN European Organization for Nuclear Research) – August 31, 2019
Summary
Unlocking the brain's capacity for change, clinical psychology explores how psilocybin can reshape personality. This work in Psychology and Psychedelics and Drug Studies investigates how "Openness to experience" and its neural correlates of consciousness shift in treatment-resistant depression. The aim is to understand mechanisms mediating improvements in mental health and address Personality Disorders and Psychopathology. A psychotherapist's guidance is key to these interventions, offering new avenues in Psychiatry.
Abstract
This document is my Master's Thesis for the Research Master Cognitive Neuroscience program at Maastricht University. The present study investigated...
Akzeptanz psilocybin-assistierter Therapie in den deutschsprachigen Ländern
edoc Publication server (Humboldt University of Berlin) – February 12, 2025
Summary
Optimism for psilocybin-assisted therapy is high, especially among informed individuals. A survey of 1456 participants, including medical professionals and patients, revealed greater knowledge and personal psychedelic experience predicted significantly more positive attitudes toward its implementation (explaining 39% of variance). Acceptance for this innovative Medicine, relevant to Pain Management and broader well-being, increased when information about therapeutic potentials was balanced with risks. This highlights the importance of informed public discourse, crucial for integrating advances from Psychedelics and Drug Studies and shaping sound policy.
Abstract
Hintergrund: Klinische Studien mit Psilocybin in Kombination mit Psychotherapie zeigen vielversprechende Ergebnisse bei der Behandlung verschiedene...
Psilocybin-Based Breakthroughs in Natural Medicine
Case Reports and Reviews – April 30, 2023
Summary
Psilocybin, a natural hallucinogen derived from mushrooms, profoundly alters perception, offering new hope for mental anguish. This alkaloid, historically used since ancient times, activates brain regions, fostering novel cognition. Neuroscience and psychiatry are actively exploring its medical potential. Cognitive psychology suggests psilocybin-assisted therapy, guided by a psychotherapist, could revolutionize treatment for emotional and physical pain. Psychedelics and Drug Studies, alongside Complementary and Alternative Medicine, consider this a significant breakthrough, despite its medical application being nascent.
Abstract
Nature created a mushroom-based compound known as psilocybin that can biochemically alter perception and affect mental anguish. Medical research sh...
How Important Is a Guide Who Has Taken Psilocybin in Psilocybin-Assisted Therapy for Depression?
Journal of Psychoactive Drugs – March 23, 2022
Summary
Potential clients for Psilocybin-Assisted Therapy (PAT) for depression strongly prefer a psychotherapist who has personally experienced the hallucinogen. Over 800 individuals with depressive symptoms rated a guide's psilocybin use as highly important, exceeding a "somewhat important" benchmark of 50 on a 100-point scale. This Psychology and Clinical psychology insight suggests a guide's personal psychedelics experience could enhance PAT's antidepressant effects. People of color and those with prior therapy especially valued this, impacting future psychiatry protocols and complementary medicine approaches.
Abstract
Promising outcomes of Psilocybin-Assisted Therapy (PAT) for depression have generated concerted efforts to replicate, extend, and refine protocols ...
Comment and Response: (Lugo-Radillo & Cortez-Lopez, 2020) Long-Term Amelioration of OCD Symptoms in a Patient with Chronic Consumption of Psilocybin-Containing Mushrooms
Journal of Psychoactive Drugs – January 27, 2022
Summary
A compelling case documented a single individual experiencing reduced obsessive-compulsive disorder (OCD) symptoms after psilocybin consumption. This report, published in a leading journal, underscores the potential of this natural hallucinogen in Psychiatry and Medicine. While such findings from Complementary and Alternative Medicine Studies are intriguing for Psychology, the broader field of Psychedelics and Drug Studies increasingly emphasizes rigorous clinical trials. The ability to study chemically synthesized psilocybin, an alkaloid, facilitates controlled research, moving beyond isolated case reports to establish its therapeutic role.
Abstract
The Journal of Psychoactive Drugs published a case study reporting reduction of obsessive-compulsive disorder (OCD) symptoms after consumption of p...
Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l’étude
The Canadian Journal of Psychiatry – March 25, 2025
Summary
Patients experiencing major depressive episodes achieved comparable relief from depression, anxiety, and suicidal ideation, whether they tapered off antidepressants (n=18) or were unmedicated (n=9) when receiving psilocybin-assisted psychotherapy. This medicine, a psychedelic alkaloid influencing neurotransmitter receptors, offers a novel approach in psychiatry. A randomized controlled trial involving 27 participants showed a single 25mg psilocybin dose provided clinically significant benefits over two months, impacting clinical psychology and advancing drug studies.
Abstract
Objective: To compare changes in depression, anxiety, and suicidality symptoms after a single 25 mg oral dose of psilocybin between treatment-resis...
Perceptions of Psilocybin-Assisted Psychotherapy and Standard Interventions for Nicotine Cessation
Journal of Psychoactive Drugs – January 01, 2026
Summary
Credibility powerfully predicts daily nicotine users' willingness to engage with smoking cessation interventions, especially novel psychological support like psilocybin-assisted psychotherapy (β = 0.71). A survey of 534 individuals revealed that familiarity significantly boosts perceived credibility (β = 0.36 for psilocybin; β = 0.16 for standard pharmacotherapy or cognitive behavioral therapy). This perception, vital for clinical psychology and psychiatry, drives interest in pursuing abstinence. Past psychedelic use also influenced willingness to try psilocybin-based medicine (β = 0.10).
Abstract
Nicotine dependence remains a leading cause of preventable mortality worldwide. Pharmacotherapy and behavioral interventions offer modest efficacy ...
Divergent Effects of Psilocybin for 2 Patients Participating in a Psilocybin-assisted Cognitive Behavioral Therapy Trial for Major Depressive Disorder.
Journal of psychiatric practice – May 01, 2025
Summary
Psilocybin combined with cognitive behavioral therapy showed dramatically different outcomes in treating major depressive disorder: one patient experienced lasting relief while another saw minimal benefits. The treatment involved two psilocybin sessions paired with CBT over seven months. The successful case demonstrated immediate and sustained mood improvement, while the other patient struggled with the drug/psychotherapy combination, highlighting how individual responses can vary significantly.
Abstract
We present divergent experiences of 2 patients who participated in a clinical trial of psilocybin-assisted cognitive behavioral therapy for major d...
Divergent Effects of Psilocybin for 2 Patients Participating in a Psilocybin-assisted Cognitive Behavioral Therapy Trial for Major Depressive Disorder
Journal of Psychiatric Practice – May 01, 2025
Summary
Psilocybin, a potent hallucinogen, shows highly variable effects for major depressive disorder. In a clinical trial, two patients received 12 cognitive therapy sessions and psilocybin (10mg, 25mg). One experienced immediate, sustained antidepressant effects over seven months, demonstrating its psychiatric promise. Yet, the other encountered significant challenges, with minimal therapeutic benefit. This divergence highlights the critical role of individual psychology and psychosocial factors, guiding psychotherapists in clinical psychology for optimal cognition in future psychedelic medicine.
Abstract
We present divergent experiences of 2 patients who participated in a clinical trial of psilocybin-assisted cognitive behavioral therapy for major d...
Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin.
Med (New York, N.Y.) – March 08, 2024
Summary
Psilocybin combined with psychotherapy shows remarkable promise for treating stubborn depression. In this groundbreaking work, patients with major depressive disorder and bipolar disorder who hadn't responded to conventional treatments received up to three 25mg psilocybin doses alongside therapy. Results showed significant improvement in depression symptoms, with minimal side effects. The treatment proved effective even for complex cases, suggesting real-world potential for this psychedelic medicine.
Abstract
Psilocybin-assisted psychotherapy (PAP) has been associated with antidepressant effects. Trials to date have typically excluded participants with c...
Psilocybin-Assisted Therapy Found to Improve Depression, Offer Other Benefits
Psychiatric News – May 23, 2022
Summary
Psilocybin therapy offers substantial, lasting relief for major depression. In a group of 24 individuals, this hallucinogen, combined with psychotherapy, led to 75% achieving treatment response and 58% remission after one year, with no serious adverse effects. This advance in Psychiatry and Clinical psychology, impacting Medicine, highlights psychedelics' potential in Mental Health Research Topics, even if personal meaning didn't directly predict depression improvement.
Abstract
Back to table of contents Previous article Next article Clinical & ResearchFull AccessPsilocybin-Assisted Therapy Found to Improve Depression, Offe...
Psilocybin-assisted therapy for individuals with palliative care needs: A systematic review of safety and efficacy
Palliative Medicine – December 18, 2025
Summary
For patients facing end-of-life challenges, psilocybin-assisted therapy dramatically reduces depression and anxiety. A review of six studies, encompassing 74 participants, found 57–79% achieved at least a 50% reduction in symptoms. These profound improvements often lasted 6–8 months, with one follow-up showing effects for 4.5 years. Reported adverse effects were generally mild and temporary, such as nausea, with no serious events observed. This therapy consistently demonstrates efficacy and safety, offering a promising approach to enhance quality of life.
Abstract
Background: Palliative Care is concerned with relieving suffering and improving the quality of life of patients and their families. Currently, ques...
UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – November 01, 2023
Summary
Psilocybin's effects on the brain vary dramatically based on setting, with the compound reshaping neural communication patterns across multiple brain regions. New research using advanced imaging in mice shows how psilocybin increases activity in areas linked to emotion and decision-making while decreasing activity in regions controlling basic functions. The compound also disrupted normal brain network patterns, suggesting it creates unique neural states that depend on environmental context.
Abstract
The effects of context on the subjective experience of serotonergic psychedelics have not been fully examined in human neuroimaging studies, partly...
Social acceptability of psilocybin-assisted therapy for existential distress at the end of life: A population-based survey
Palliative Medicine – January 22, 2024
Summary
Nearly 80% of Canadians embrace psilocybin-assisted therapy as a reasonable medical choice for existential distress at the end of life. A survey of 2800 adults across four provinces found 79.3% considered it acceptable, with 84.8% advocating for public health coverage. A significant 63.3% also favored legalizing psilocybin for medical purposes. This high social acceptability suggests a growing openness to this emerging form of medicine within palliative and end-of-life care, influencing future psychology and psychiatry practices.
Abstract
Background: Internationally, there is a growing interest in the potential benefits of psilocybin-assisted therapy to treat existential distress at ...
The History, Legalization and Potentials of Psilocybin-Assisted Psychotherapy
Journal of Scientific Exploration – February 11, 2023
Summary
Recent clinical trials reveal a profound impact from psilocybin, a unique hallucinogen derived from natural alkaloids, when integrated into psychological interventions. This chemical compound, historically used in shamanic rituals, is showing significant benefits for distress like end-of-life anxiety and severe depression. Psychotherapists are exploring its potential, shifting perspectives in clinical psychology and psychiatry. The relevance (law) of psilocybin's legalization is a growing debate, as psychedelics and drug studies highlight its therapeutic promise. This innovative approach, involving specific psychotherapy techniques, is reshaping our understanding of mental health.
Abstract
The potential benefits and deficits of the chemical compound psilocybin, particularly when paired with psychotherapeutic interventions, have ...
Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences.
Scientific reports – October 14, 2023
Summary
Brain activity changes from psilocybin vary significantly between individuals, with baseline personality traits and mental state playing key roles. Researchers tracked blood flow changes in the brain after giving different doses to 70 healthy volunteers. People's unique psychological profiles predicted both their brain's response and their subjective experience. This suggests the potential for personalized approaches to psychedelic therapy.
Abstract
Research into the use of psilocybin for the treatment of psychiatric disorders is a growing field. Nevertheless, robust brain-behavior relationship...
The association between diverse psychological protocols and the efficacy of psilocybin-assisted therapy for clinical depressive symptoms: a Bayesian meta-analysis
Frontiers in Psychiatry – August 13, 2024
Summary
Surprisingly, the type of psychological support offered alongside psilocybin treatment doesn't significantly alter its effectiveness for clinical depression. A meta-analysis of 10 studies, involving 515 adult patients, explored how different psychotherapist approaches, from manualized directive to non-manualized supportive, impacted outcomes. Psilocybin, a psychedelic alkaloid, showed a strong standardized mean difference of 10.08 in reducing depressive symptoms. This suggests that while psilocybin-assisted therapy holds promise in psychiatry and clinical psychology, the specific psychological protocol may be less critical than previously thought in these Complementary and Alternative Medicine Studies.
Abstract
Objective Psilocybin-assisted therapy has shown promising efficacy on clinical depressive symptoms. However, diverse psychological support or psych...
The safety of psilocybin-assisted psychotherapy: A systematic review
Australian & New Zealand Journal of Psychiatry – December 13, 2024
Summary
No deaths were attributed to psilocybin, a hallucinogen showing promise in medicine. A systematic review of 24 clinical trials in clinical psychology and psychiatry found that while adverse effects like headaches, nausea, and anxiety were common during psilocybin-assisted psychotherapy, serious issues were rare. Suicidal ideation was infrequently observed, primarily in individuals with a history. This comprehensive look at Psychedelics and Drug Studies highlights the general safety of this alkaloid, though standardizing adverse effect reporting for psychotherapists is crucial for future clinical trials.
Abstract
Introduction: Psilocybin, a classical psychedelic, has been rescheduled for use in psilocybin-assisted psychotherapy for treatment-resistant depres...
Psilocybin-Assisted Therapy Increases Self-Compassion in Patients with Alcohol Use Disorder
OpenAlex – June 10, 2025
Summary
Psilocybin-assisted therapy, guided by a psychotherapist, robustly increased self-compassion in 44 adults with alcohol use disorder, compared to 42 receiving placebo. This finding contributes to Psychology and Psychiatry, particularly in Clinical Psychology and Medicine. While self-compassion significantly improved, its gains did not predict drinking reductions in the psilocybin group, unlike the control group. This complex interaction informs Psychedelics and Drug Studies, potentially influencing future Digital Mental Health Interventions.
Abstract
A recent randomized, double-blind, placebo-controlled, parallel-group trial (NCT02061293) found that psilocybin-assisted therapy significantly impr...
What do health professionals think about implementing psilocybin-assisted therapy in palliative care for existential distress? A World Café qualitative study.
Palliative & supportive care – October 01, 2024
Summary
Healthcare providers show growing interest in psilocybin-assisted therapy for end-of-life care, particularly for treating existential distress in terminal patients. In a gathering of 16 palliative care professionals, participants expressed optimism about this treatment while highlighting practical needs: standardized training, clear protocols, and proper facility requirements. The therapy shows promise for easing psychological suffering in terminal illness.
Abstract
Promising studies show that psilocybin-assisted therapy relieves existential distress in patients with serious illnesses, a difficult condition to ...
What do health professionals think about implementing psilocybin-assisted therapy in palliative care for existential distress? A World Café qualitative study
Palliative & Supportive Care – October 01, 2024
Summary
Psilocybin-assisted therapy shows great promise for alleviating existential distress in palliative care, a difficult condition for conventional medicine. Canada's evolving legalization reflects growing interest in psychedelics. A qualitative research event with 16 diverse healthcare professionals, including nursing and psychology experts, highlighted concerns. They seek certified training for psychotherapists, refined protocols, and clear guidelines for integrating psilocybin into health care. Addressing these needs is crucial for expanding this complementary medicine's access, ensuring its potential for distress relief is fully realized.
Abstract
Abstract Objectives Promising studies show that psilocybin-assisted therapy relieves existential distress in patients with serious illnesses, a dif...
Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder
Frontiers in Psychiatry – March 14, 2023
Summary
Current psychological interventions for methamphetamine use disorder yield modest success, leaving a critical gap in Psychiatry and Medicine. Yet, the potent hallucinogen psilocybin, an alkaloid with known Neurotransmitter Receptor Influence on Behavior, presents a promising avenue. While no Clinical psychology studies exist for this specific application, Psychedelics and Drug Studies are investigating psilocybin-assisted psychotherapy. This innovative psychological intervention, combining a psychotherapist with psilocybin (a compound from chemical synthesis), offers new hope in Psychology to revolutionize treatment where current medicine falls short.
Abstract
Methamphetamine use disorder is a chronic relapsing condition associated with substantial mental, physical, and social harms and increasing rates o...
Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis
Journal of Humanistic Psychology – April 28, 2017
Summary
Psilocybin-assisted psychotherapy profoundly alleviates psychological distress. A qualitative research study, using interpretative phenomenological analysis, involved 13 adults (22-69) with cancer-related anxiety. Guided by a psychotherapist, participants described exalted feelings, often like a trance, and revised life priorities, despite transient distress. This work, relevant to Psychology, Complementary and Alternative Medicine Studies, and Drug Studies, explores Psilocybin’s transformative potential. As a psychedelic compound, its effects, rooted in chemical synthesis and alkaloids, offer new avenues for well-being.
Abstract
The psychological mechanisms of action involved in psilocybin-assisted psychotherapy are not yet well understood. Despite a resurgence of quantitat...
Roadmap for Equitable Access and Responsible Use of Psilocybin-Assisted Psychotherapy in Palliative Care
Palliative Medicine Reports – April 17, 2025
Summary
Psilocybin, a potent hallucinogen, shows promise in palliative care, enhancing quality of life by easing existential distress. Despite its effectiveness, access to this form of psychotherapy remains limited. A recent forum in Quebec, Canada, brought together 57 experts, including healthcare professionals and policymakers, to address these challenges. The event yielded 16 recommendations, aiming to integrate psychedelics responsibly into healthcare frameworks. This initiative helps expand access to vital mental health support, reflecting growing interest in Complementary and Alternative Medicine Studies and the potential of chemical synthesis and alkaloids in psychiatry.
Abstract
Psilocybin-assisted psychotherapy represents a promising addition to palliative care interventions, potentially improving quality of life by addres...
Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial.
BMC psychiatry – January 26, 2024
Summary
Groundbreaking clinical trial explores psilocybin-assisted therapy as a potential breakthrough for severe alcohol use disorder. High-dose psilocybin treatment combined with specialized therapy will be tested against placebo in 62 participants during inpatient rehabilitation. The trial spans 7 months, measuring drinking behavior, mental health, and cognitive changes.
Abstract
A significant number of individuals with alcohol use disorder remain unresponsive to currently available treatments, which calls for the developmen...
Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Protocol for a Double-Blind, Randomized, Placebo-Controlled, 7-month Parallel-Group Phase II Superiority Trial
Research Square (Research Square) – January 04, 2024
Summary
A promising new intervention aims to tackle severe alcohol use disorder. A double-blind, randomized controlled trial will involve 62 participants, exploring psilocybin-assisted therapy within a robust inpatient rehabilitation context. One group receives 30mg psilocybin, while another gets an active 5mg placebo, alongside counseling. This clinical psychology and psychiatry study, part of broader psychedelics and drug studies, will assess changes in drinking behavior and neurocognitive mechanisms, examining how this alkaloid influences neurotransmitter receptors. This medicine aims to offer a new path for those struggling with addiction.
Abstract
Abstract Background: A significant number of individuals with alcohol use disorder remain unresponsive to currently available treatments, which cal...
Systematic study of Panaeolus (Agaricales, Galeropsidaceae) sensu lato and psilocybin-producing traits of species from China
Global Biodiversity Information Facility – January 01, 2026
Summary
A new species from China is among two of 14 *Panaeolus sensu lato* species confirmed to produce psilocybin, a key finding in fungal biology. This systematic revision establishes the panaeo-clade as the distinct Galeropsidaceae family. The taxonomy clarifies nomenclature for the Genus *Panaeolus*, now accepting three Subgenus groups, including *Bresadolomyces* with an expanded circumscription. Eight new species were identified, advancing understanding of this species complex and its ecology, extending beyond traditional zoology.
Abstract
This dataset contains the digitized treatments in Plazi based on the original journal article He, Mao-Qiang, Yang, Wen-Qiang, Phurbu, Dorji, Liu, F...
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up
Journal of Psychopharmacology – February 01, 2022
Summary
Psilocybin-assisted therapy offers remarkable long-term antidepressant effects for major depressive disorder. A randomized controlled trial with 24 participants showed 75% achieved treatment response and 58% remission after 12 months. Sustained, large decreases in Hamilton Rating Scale for Depression (Hamd) scores (Cohen d up to 2.6) were observed. No serious adverse effects occurred within the study's context. This medicine, a psychedelic alkaloid, shows promise for psychiatry and clinical psychology, advancing psychedelics and complementary medicine studies.
Abstract
Background: Preliminary data suggest that psilocybin-assisted treatment produces substantial and rapid antidepressant effects in patients with majo...
Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation
Psychopharmacology – January 07, 2025
Summary
A single high dose of psilocybin, combined with therapy, significantly improved mental health, lowering anxiety, depression, PTSD, and neuroticism for three months. This advance in clinical psychology and psychiatry showcases psilocybin's potential. Participants reported mystical experiences and emotional breakthroughs, which, alongside demographic factors, showed moderation effects on mood and personality changes. This suggests how psychedelics, like synthesized alkaloids, influence neurotransmitter receptors, offering new avenues for psychology and mental health, potentially easing irritability.
Abstract
Abstract Rationale Psychedelic-assisted therapy is increasingly applied within mental health treatment. Objectives This study focused on factors mo...
Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief (PARTING) trial: protocol for an open-label pilot trial for cancer-related bereavement
BMJ Open – April 01, 2025
Summary
Up to 30% of bereaved oncology carers suffer prolonged grief, with current treatments failing 50%. A new clinical trial explores Psilocybin as Medicine for Grief. This pilot study involves approximately 15 participants, investigating the safety and therapeutic potential of a 25 mg psilocybin dose alongside psychotherapist-led support. Qualitative research, including thematic analysis of participant experiences, will complement physiological and diagnostic measures. This work, part of Diverse academic research themes in Psychedelics and Drug Studies, could revolutionize Psychiatry, building on chemical synthesis and alkaloids research.
Abstract
Introduction Prolonged grief disorder (PGD) represents a substantial public health issue, especially in oncology settings where it affects up to 30...
A Cohort Based Case Series: Learnings from an Iterative Group Therapy Model to Support Psilocybin-Assisted Therapy for Patients with a Terminal Diagnosis
European Psychiatry – April 01, 2024
Summary
A new group psychotherapy model successfully helped 21 of 25 participants (84%) facing terminal health conditions. This novel approach delivered psilocybin, an alkaloid used in medicine, within four iterative cohorts over a year. Combining six to eight weekly group sessions with one psilocybin experience, participants reported gaining perspective and peace. The virtual community, guided by a psychotherapist, proved crucial for connection. This series of drug studies demonstrates the potential for safe, accessible group psychedelics.
Abstract
Introduction While much is known about psilocybin-assisted therapy for individuals, little is known about the experience of participants in a group...
Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders
Journal of Psychoactive Drugs – May 08, 2017
Summary
The hallucinogen psilocybin shows compelling promise for psychiatry. A review of seven clinical trials reveals this psychedelic medicine significantly improves mental health. Participants experienced large effect sizes for reduced anxiety and depression symptoms. Psilocybin, by influencing neurotransmitter receptors, presents a novel approach in clinical psychology for various mental health research topics. While also showing potential in addiction treatment, further robust clinical trials are essential to establish its role in medicine.
Abstract
Recent research suggests that functional connectivity changes may be involved in the pathophysiology of psychiatric disorders. Hyperconnectivity in...
Long-term Amelioration of OCD Symptoms in a Patient with Chronic Consumption of Psilocybin-containing Mushrooms
Journal of Psychoactive Drugs – November 22, 2020
Summary
A man with severe Obsessive Compulsive Disorder experienced a clinically meaningful symptom reduction after consuming psilocybin, a potent hallucinogen. This promising case, significant for Psychiatry and Psychology, underscores the potential of psychoactive substances in Medicine. Given that conventional OCD treatments often fall short, early observations in Psychedelics and Drug Studies suggest compounds like psilocybin could offer new therapeutic avenues. This aligns with growing interest in Complementary and Alternative Medicine.
Abstract
Obsessive Compulsive Disorder (OCD) is a chronic neuropsychiatric condition, characterized by obsessions and compulsions, which is usually disablin...
Psilocybin-induced default mode network hypoconnectivity is blunted in alcohol-dependent rats
Translational Psychiatry – December 14, 2023
Summary
Neuroscience reveals psilocybin, a potent hallucinogen, may require personalized dosing for Alcohol Use Disorder (AUD). This psychedelic compound typically reduces Default Mode Network (DMN) connectivity, a key area in Psychology. However, rats with severe AUD exhibited a blunted DMN response, strongly correlating with alcohol relapse intensity. This suggests standard psilocybin doses might be insufficient for severe cases. This pharmacology insight, vital for Medicine and Psychiatry, highlights Neurotransmitter Receptor Influence on Behavior and Tryptophan and brain disorders in AUD treatment.
Abstract
Abstract Alcohol Use Disorder (AUD) adversely affects the lives of millions of people, but still lacks effective treatment options. Recent advancem...
The Role of Psilocybin-Assisted Psychotherapy to Support Patients With Cancer: A Critical Scoping Review of the Research
Journal of Holistic Nursing – September 06, 2021
Summary
Psilocybin-assisted psychotherapy offers profound hope for cancer patients struggling with persistent mental health issues, despite conventional psychiatry. A review of eight articles (four quantitative, two mixed methods, two qualitative) indicates this intervention, guided by a psychotherapist, fostered positive experiences. Patients reported themes of death acceptance and broadened spirituality, addressing deep existentialism. This emerging approach in clinical psychology and palliative care, utilizing psilocybin (a naturally occurring alkaloid), complements traditional medicine and drug studies, providing a novel mental health strategy in psychedelics and alternative medicine.
Abstract
Treatments for addressing psychiatric mental health issues in vulnerable patients with cancer are established. Yet, many patients persist with unre...
Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations
Neuropharmacology – May 13, 2022
Summary
Psilocybin-facilitated psychotherapy offers profound promise for mental health. Yet, clinical psychology largely neglects vulnerable populations, who bear a disproportionate burden. Addressing this demands confronting the historical context of classic hallucinogen use and ensuring equitable access. Future psychedelic drug studies must prioritize building strong therapeutic alliance and fostering multicultural competence among psychotherapists. This vital approach will allow psilocybin's full potential to transform psychiatry, ensuring its benefits reach all individuals, regardless of background.
Abstract
Psilocybin-facilitated psychotherapy shows potential transdiagnostic efficacy for a range of mental health conditions. Though vulnerable population...